Literature DB >> 29214369

Ginkgolide K promotes the clearance of A53T mutation alpha-synuclein in SH-SY5Y cells.

Wenbo Yu1, Sheng Chen1, Liang Cao2, Jie Tang1, Wei Xiao2, Baoguo Xiao3.   

Abstract

Alpha-synuclein (α-syn) is associated to Parkinson's disease (PD). The aggregated form of α-syn has potential neurotoxicity. Thus, the clearance of α-syn aggregation is a plausible strategy to delay disease progression of PD. In our study, we found that the treatment of Ginkgolide B (GB) and Ginkgolide K (GK) reduced cell death, and enhanced cell proliferation in SH-SY5Y cells, which overexpressed A53T mutant α-syn. Surprisingly, GK, but not GB, promoted the clearance of A53T α-syn, which can be abolished by autophagy inhibitor 3-methyladenine, indicating that GK-induced autophagy intervened in the clearance of A53T α-syn. However, GK did not affect the NEDD4 that belongs to the ubiquitin ligase in the endosomal-lysosomal pathway. Furthermore, GK treatment inhibited the p-NF-kB/p65 and induced the PI3K, BDNF, and PSD-95. Taken together, GK increased the clearance of α-syn, reduced cell death, and triggered complex crosstalk between different signaling pathways. Although our results show a potentially new therapeutic candidate for PD, the details of this mechanism need to be further identified.

Entities:  

Keywords:  Alpha-synuclein; Autophagy; Ginkgolide B; Ginkgolide K

Mesh:

Substances:

Year:  2017        PMID: 29214369     DOI: 10.1007/s10565-017-9419-4

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  2 in total

1.  Antioxidant effects of ginkgolides and bilobalide against cerebral ischemia injury by activating the Akt/Nrf2 pathway in vitro and in vivo.

Authors:  Qiu Liu; Zhiquan Jin; Zhiliang Xu; Hao Yang; Liang Li; Guiping Li; Fang Li; Shaoli Gu; Shaobo Zong; Jun Zhou; Liang Cao; Zhenzhong Wang; Wei Xiao
Journal:  Cell Stress Chaperones       Date:  2019-02-27       Impact factor: 3.667

2.  Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Authors:  Yu-Chen Yan; Zhi-Heng Xu; Jian Wang; Wen-Bo Yu
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.